Lithuanian-based startup Ligence, which develops AI-powered cardiac diagnostics software, has raised €3 million in seed funding. The investment round was led by Simpact Ventures, a Polish VC firm specializing in social impact technologies, with participation from Coinvest Capital, the European Innovation Council (EIC) Fund, Estonian VC Lemonade Stand, business angel syndicate NGL, and investor Rita Sakus.

Founded in 2020, Ligence is on a mission to improve cardiac ultrasound diagnostics using artificial intelligence. Its software automates echocardiography image analysis, empowering cardiologists to make faster and more accurate clinical decisions.

Funding Details

Simpact Ventures, the lead investor, emphasized Ligence's social impact goals. “Ligence not only improves diagnostics for heart disease—the world’s leading cause of death—but also reduces clinical workloads, allowing doctors to focus on patient care,” said Wojciech Majewski, Partner at Simpact Ventures.

The round also featured strong backing from Coinvest Capital. “We see Ligence’s clear potential both as a business and a purpose-driven company. Their recognition at ‘Startup Fair. Pulse 2024’ highlights the value the investment community sees in their innovation,” noted Viktorija Trimbel, Director at Coinvest Capital.

NGL also contributed, led by founder Justinas Pašys, who praised Ligence’s strong momentum: “With clinical trials in leading US hospitals and growing traction, Ligence is delivering a world-class solution. Their ability to streamline diagnostics and improve healthcare efficiency is impressive.”

Market Reach and Clinical Trials

Ligence’s software is already operational in multiple European countries, including Lithuania, Poland, Switzerland, Germany, France, Spain, Portugal, and the UK, and is being tested in Morocco. Ongoing clinical trials are underway in the United States, Germany, the Netherlands, Poland, and Lithuania.

Purpose and Future Goals

Ligence combines business growth with social impact. Its technology enhances diagnostic precision, improves risk assessment, and reduces manual workloads for doctors. By adhering to ASE and ESC guidelines and integrating with hospital PACS systems, Ligence ensures transparent and standardized cardiac diagnostics.

The new funding will help Ligence expand its product capabilities, enhance clinical partnerships, and further its mission to fight cardiovascular disease—improving patient care globally while increasing healthcare efficiency.

At NGL we invest in startups via investment syndicates because there are many benefits of sharing competences, risks, and costs when investing in startups. First of all, it helps attract more and better deal flow due to the combined larger ticket. It also allows angels to invest smaller sums per startup, making more deals, building a portfolio, and diversifying. We also make collective analysis and decisions leveraging the expertise of our investor group.